# OnCo record paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014" ;
  schema:name "RAINBOW: ramucirumab plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric cancer"@en ;
  schema:description "Adding the anti-VEGFR2 antibody ramucirumab to weekly paclitaxel lengthened survival by over two months in gastric cancer that had progressed after first-line chemotherapy, establishing the standard second-line regimen."@en ;
  schema:url <https://onco.cc/key-papers/paper-rainbow-ramucirumab-paclitaxel-lancet-oncol-2014/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(14)70420-6>, <https://pubmed.ncbi.nlm.nih.gov/25240821/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(14)70420-6> ;
  schema:datePublished "2014"^^xsd:gYear ;
  schema:author "Wilke H, Muro K, Van Cutsem E, et al." ;
  onco:cancers <https://onco.cc/cancers/gastric-pdl1-high/>, <https://onco.cc/cancers/gastric-cldn18-2-positive/> ;
  onco:drugs <https://onco.cc/drugs/ramucirumab/> ;
  onco:trials <https://onco.cc/trials/rainbow/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .